Introduction {#sec1}
============

Hypothyroidism is one of the radiation therapy (RT)-attributable side effects after curative treatment of head and neck cancers (HNC).[@bib1], [@bib2], [@bib3] It has been reported that 19% to 53%[@bib4], [@bib5] of the HNC patients develop hypothyroidism after RT, which negatively affects quality of life in HNC survivors.[@bib6] This is of particular importance in the era of human papillomavirus (HPV) positive oropharyngeal carcinoma (OPC) with rapidly growing numbers of (young) survivors who live decades with treatment morbidities.[@bib7], [@bib8] The vast majority of modern OPC patients are treated with RT as a component of their care.[@bib9] Refinements in RT delivery can lessen nontarget doses in hopes of toxicity reduction.[@bib10], [@bib11] Yet, even with modern RT, toxicity prediction strategies are needed because collateral dose to normal tissue is unavoidable without compromising the therapeutic RT dose required to eradicate the tumor.[@bib12]

Even with intensity-modulated radiation therapy (IMRT), higher hypothyroidism rates have been reported[@bib13], [@bib14] and this phenomenon could be elucidated by the IMRT beam path parameters, namely higher integral radiation dose to nontarget normal tissues.[@bib15] However, with IMRT, application of additional dose constrains that would decrease the delivered RT dose to the thyroid gland (TG) is feasible.[@bib13] To use the modern RT techniques for risk-adapted RT plans, identifying clinical and dosimetric parameters for modeling normal tissue complication probability (NTCP) is an unmet clinical need.[@bib16] Currently, there is a growing effort to identify the relevant input clinical and dosimetric parameters that could be incorporated in an NTCP model for hypothyroidism.[@bib17], [@bib18] At present, some dosimetric parameters (ie, mean thyroid gland dose, V30, V40, and V50) have been proposed to minimize the risk of hypothyroidism after RT.[@bib19], [@bib20], [@bib21], [@bib22] Nevertheless, NTCP models that account for the patient-intrinsic risk factors[@bib23] and treatment parameters could offer a powerful approach for personalized treatment selection and RT plan optimization based on estimated risk of complications.

This work aims to apply existing NTCP models for radiation-induced hypothyroidism (RHT) risk prediction in a large cohort of OPC patients and to explore the clinical and dosimetric parameters for RHT.

Methods and Materials {#sec2}
=====================

Study cohort {#sec2.1}
------------

We identified 523 OPC patients treated with IMRT without thyroidectomy at University of Texas, MD Anderson Cancer Center, between 2007 to 2013. OPC patients treated with retrievable IMRT plan or dose DICOMs and known baseline thyroid status and available follow-up thyroid function tests were included ([Fig E1](#appsec1){ref-type="sec"}, available online at <https://doi.org/10.1016/j.adro.2019.08.006>). In total, 360 OPC patients were eligible for the analysis. Clinical HT that required thyroid replacement therapy was defined as grade ≥2 HT per Common Terminology Criteria for Adverse Events grading system, versions 3 and 4[@bib24]^,^[@bib25] at least 6 months post-RT.

Intensity modulate radiation therapy {#sec2.2}
------------------------------------

Treatment planning was conducted using Pinnacle 9.6 software in all patients (Philips Medical Systems, Andover, MA). All patients were treated with IMRT, per our institutional protocol for OPC,[@bib26] with each case undergoing rigorous group peer-review prior treatment commencement.[@bib27] IMRT was delivered using split-field[@bib28] technique for most of the patients. Whole-field IMRT was used only for bulky tumors, which might be underdosed using the split-field approach. We are following the National Comprehensive Cancer Network guidelines[@bib29] for the sequential and concurrent systemic therapy.

Dosimetric data {#sec2.3}
---------------

Treatment plan and dosimetric data were restored using Pinnacle 14 software (Phillips Medical Systems, Andover, MA). Planning CT DICOM files were exported into a benchmarked[@bib30] commercial deformable registration/segmentation software Velocity AI (Velocity AI 3.0.1, Velocity Medical Solutions, Atlanta, GA). Mean dose (Dmean) to the TG and its volume were calculated using Velocity AI software. Thyroid gland was autosegmented using a previously validated atlas data set[@bib30] and subsequently curated by expert radiation oncologists (MK and ASRM). Dose-volume histograms (DVHs) were extracted from Velocity AI.

Normal tissue complication probability modeling {#sec2.4}
-----------------------------------------------

Two previously published NTCP models for hypothyroidism were selected to be tested on our institution's data set. One model has been published by Boomsma et al,[@bib18] which uses the logistic function.$$NTCP = \frac{1}{1\  + e^{- S}}$$

In Equation [1](#fd1){ref-type="disp-formula"}, S is a linear function determined through a generalized linear model fit based on mean thyroid dose and thyroid volume and has the form.$$S = \ 0.011\  + \left( {0.062 \ast mean\ dose\ thyroid\ galnd} \right) + \left( {- 0.19 \ast thyroid\ gland\ volume} \right)$$

The second model was enumerated by Cella et al,[@bib31] and it incorporates thyroid V~30~, the absolute volume (in mL) of the thyroid gland receiving a dose of 30 Gy, the absolute total volume of the thyroid gland, and sex. The associated S function is Equation [3](#fd3){ref-type="disp-formula"}, which can be applied through Equation [1](#fd1){ref-type="disp-formula"}.$$S = \ 1.94\  + \left( {0.26 \ast thyroid\ V_{30}} \right) + \left( {- 0.27 \ast thyroid\ gland\ volume} \right) + \left( {- 2.21 \ast sex\ \left( {male} \right)} \right)$$

For both of the selected models, a model of the same form was fit on our institution's data set similarly using generalized linear model fitting with a logit link function. Additionally, several models similar to Equation [2](#fd2){ref-type="disp-formula"} but instead using equivalent uniform dose (EUD) were also fit. EUD was calculated according to Equation [4](#fd4){ref-type="disp-formula"}, incorporating values of the *a* parameter including 0.5, 2, 3, 4, and 5.$$EUD = \left( {\sum\limits_{i\  = \ 1}^{n}{v_{i}D_{i}^{a}}} \right)^{\frac{1}{a}}$$where v~i~ and D~i~ describe the differential volume and dose, respectively. The *a* parameter value of 1 was omitted because in that case the EUD is equal to the mean dose.

Model fitting was carried out using the glm function in R version 3.4.2.[@bib32] The predictive ability of the selected models and the fitted models were compared based on receiver operating characteristic (ROC) curves, which were calculated with the pROC package in R.[@bib33] The ROC curves for the fitted models were calculated based on 10-fold repeated cross-validation with 100 repeats. The area under the curve (AUC) values for the various models were then compared according to DeLong's test for 2 correlated ROC curves also using the pROC package.[@bib33]

Statistical analysis {#sec2.5}
--------------------

All statistical analysis was performed using commercial statistical analysis software programs (JMP v12 Pro, SAS Institute, Cary, NC; R version 3.4.2, R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics were calculated. Statistical analyses of the categorical variables were performed using χ^2^ tests and *t* tests for continuous outcomes. Dmean and volume of TG for those with HT were compared with others using Wilcoxon rank-sum test. Univariate regression models were first examined for clinical variables (T-classification, N-classification, sex, age, treatment modalities, RT dose, volume of the RT neck field and primary site). Multivariable models retained confounders that were independently associated (*P* \< .05) with the presence of clinical hypothyroidism. A *P* value of \< .05 was considered statistically significant. A Bayesian Information Criteria (BIC)-minimizing stepwise forward model was constructed using the significant clinical and dosimetric variables. Patient dose distributions were interrogated via plots of cumulative DVH (using a 1 Gy step \[range, 1-75 Gy\]) according to presence or absence of HT, with subsequent Wilcoxon rank-sum tests and *P* values plotted via heat map analysis and Bonferroni correction for multiple comparisons.

Results {#sec2.6}
-------

The study cohort includes 360 patients who were treated with IMRT for OPC. The median age was 58 years and 340 were men ([Table 1](#tbl1){ref-type="table"}). As many as 233 patients (65%) developed clinical HT after RT. The median time to develop RHT was 12 months after compilation of RT. Univariate analysis revealed that advanced tumor stage, positive nodal disease, bilateral neck irradiation, receipt of induction chemotherapy, higher Dmean to TG and smaller TG volume were associated with clinical HT. On multivariate analysis Dmean and TG volume remained statistically significant ([Table 2](#tbl2){ref-type="table"}). [Figure 1](#fig1){ref-type="fig"} shows the composite DVHs for patients with and without RHT. Our results show that patients with RHT had numerically higher dose delivery across all DVHs than those without. The cumulative DVHs showed a significant separation between the 2 groups. It is interesting that this separation is observed also in low dose regions, hinting that more effort should be spent to minimize the RT dose as low as possible. Even after Bonferroni correction, significant pairwise dose--volume differences were observed. A nonoverlapping confidence interval of dose in 1-Gy bins visually suggests a magnitude difference of *P* \< .0001 (denoted in red in the heat map). To account for multiple comparisons and avoid potential error from normal distribution assumptions while illustrating pairwise dose differentials between RHT and no RHT subgroups, a heat map is displayed below to quantify the magnitude of *P* values for each 1-Gy bin (per nonparametric Wilcoxon rank-sum test for each bin).Table 1Patient and treatment characteristicsPatient and tumor characteristicsAll patientsNo clinical HT (G0-1)Clinical HT required medications (G2)Univariate\
*P* valueN = 360N = 140N = 233N (%)N (%)N (%)Dmean mean ± SD, in Gy47.29 (±10.5)42.57 (±13.3)49.86 (±7.4)\<.0001[∗](#tbl1fnlowast){ref-type="table-fn"}TG volume mean ± SD in mL11.83 (±3.87)12.77 (±4.49)11.32 (±3.39).0076[∗](#tbl1fnlowast){ref-type="table-fn"}Age median (range), y58 (33-85)58 (35-85)58 (36-82).55Sex Male312 (87)110 (87)202 (87).98 Female48 (13)17 (13)31 (13)Subsite.0029[∗](#tbl1fnlowast){ref-type="table-fn"}Base of tongue184 (51)55 (43)129 (55) Tonsil164 (46)71 (56)93 (40) Others12 (3)1 (1)11 (5)T.0182[∗](#tbl1fnlowast){ref-type="table-fn"} 1-2259 (73)101 (80)158 (69) 3-497 (27)25 (20)72 (31) N.0050[∗](#tbl1fnlowast){ref-type="table-fn"} 024 (7)15 (12)9 (4) 1-3333 (93)111 (88)231 (96)Induction ± CCRT.0146[∗](#tbl1fnlowast){ref-type="table-fn"} Yes129 (36)35 (28)94 (40) No231 (64)92 (72)139 (60)CCRT.0574 Yes225 (63)71 (56)154 (66) No135 (38)56 (44)79 (34)HPV/P16 status.554 Positive279 (78)102 (80)177 (76) Negative29 (8)10 (8)19 (8) Unknown52 (14)15 (12)37 (16) Total RT dose, range (Gy)70 (60-72)70 (60-70)70 (60-72).054IMRT.1654 Split341 (95)123 (97)218 (94) Whole field19 (5)4 (3)15 (6)Neck irradiation.0003[∗](#tbl1fnlowast){ref-type="table-fn"} Ipsilateral45 (13)27 (21)18 (8) Bilateral315 (87)100 (79)215 (92)[^1][^2]Table 2Stepwise forward regression modelModel effectsFDR- LogWorthFDR-*P* valueWhole modelWhole modelWhole model BIC*P* valueROC, AUCDmean, median (Gy)12.326\<.0001\<.00010.7299419.8TG volume, median (mL)6.431\<.0001[^3]Figure 1Thyroid gland DVH stratified by radiation therapy-induced clinical hypothyroidism. Comparison of the dose volume histograms (DVHs) between the plans for radiation therapy-induced hypothyroidism cases versus No-HT; each error bar is constructed using a 95% confidence interval of the mean. *P* value thresholding for multiple comparisons was used with *P* \< .0006 deemed significance, which indicated in the heat map by the read shading.

Two NTCP models for hypothyroidism were fit on our institution's data following from the models selected from the literature. The model based on the Boomsma et al[@bib18] model predictors is represented by Equation [5](#fd5){ref-type="disp-formula"}.$$S = - 1.69\  + \left( {0.0879 \ast mean\ dose\ thyroid\ gland} \right) + \left( {- 0.151 \ast thyroid\ gland\ volume} \right)$$

Equation [6](#fd6){ref-type="disp-formula"} is the model which includes thyroid V~30~, total thyroid gland volume, and sex as predictors.$$S = \ 2.38\  + \left( {0.424 \ast thyroid\ V_{30}} \right) + \left( {- 0.557 \ast thyroid\ gland\ volume} \right) + \left( {0.253 \ast sex\ \left( {male} \right)} \right)$$

[Table 3](#tbl3){ref-type="table"} presents a summary of the model parameters for all models, including the parameters for each of the EUD-based models. For each value of a parameter, the corresponding EUD was significantly associated with hypothyroidism on both univariate analysis and multivariable logistic regression.Table 3Summary of model parameters and coefficients for previously published and fitted modelsModel sourceS equationCoefficients (SD error)DeLong\'s Test *P* valueabcdAUC (95% CI)Boomsma et alCella et alBoomsma et al[@bib5]a + b \* D~mean~ + c \* V~thyroid~0.0110.062--0.190.72(0.66-0.77)0.004Cella et al[@bib31]a + b \* V~30~ + c \* V~thyroid~ + d \* sex(male)1.940.26(0.09)--0.27(0.11)--2.21(0.85)0.66(0.60-0.72).004Fita + b \* D~mean~ + c \* V~thyroid~--1.49(0.63)0.0864(0.0132)--0.161(0.033)0.72(0.67-0.78).77.004Fita + b \* V~30~ + c \* V~thyroid~ + d \* sex(male)2.44(0.47)0.416(0.0731)--0.559(0.087)0.342(0.384)0.71(0.66-0.77).39.013Fita + b \* EUD~a\ =\ 0.5~ + c \* V~thyroid~--0.498(0.519)0.0674(0.0103)--0.161(0.033)0.72(0.66-0.78).78.005Fita + b \* EUD~a\ =\ 2~ + c \* V~thyroid~--3.47(0.90)0.123(0.019)--0.157(0.033)0.73(0.67-0.79).56.005Fita + b \* EUD~a\ =\ 3~ + c \* V~thyroid~--4.86(1.12)0.146(0.024)--0.151(0.033)0.72(0.67-0.78).79.010Fita + b \* EUD~a\ =\ 4~ + c \* V~thyroid~--5.69(1.28)0.159(0.026)--0.145(0.033)0.72(0.67-0.78).96.017Fita + b \* EUD~a\ =\ 5~ + c \* V~thyroid~--6.14(1.38)0.165(0.028)--0.140(0.033)0.72(0.66-0.78).91.025[^4][^5]

[Table 3](#tbl3){ref-type="table"} also presents the results for the ROC curve analysis for all models. Each of the models fit on our institution's data are compared with the performance of both the Boomsma et al[@bib18] and Cella et al[@bib31], [@bib34] models according to DeLong's test. Model performance was generally similar across all of the models with observed AUC values of approximately 0.7, with the exception of the model from Cella et al[@bib31], [@bib34] being slightly lower. The AUC for the Cella et al[@bib31], [@bib34] model was 0.66 (95% confidence interval \[CI\], 0.60-0.72), whereas that for the similar fitted model was 0.71 (95% CI, 0.66-0.77). The difference between the AUCs of the ROC curves for the 2 previously published models as applied to our data set was significant with a *P* value of .004. There was no statistically significant difference between the AUC of the ROC curve for the model from Boomsma et al[@bib18] compared with the AUCs for the models fit on our institution's data. The AUC for the Cella et al[@bib31], [@bib34] model was significantly lower (*P* \< .05) than the AUC for most of the models fit on our institution's data set. The largest AUC value (0.73; 95% CI, 0.67-0.79) was observed for the EUD-based model with an *a* parameter of 3. AUC values were similar for all tested EUD-based models with an *a* parameter \>1.

[Figure 2](#fig2){ref-type="fig"} displays mean dose to the thyroid gland versus thyroid volume for patients with and without hypothyroidism with a linear regression line and 95% confidence interval for each group. [Figure 3](#fig3){ref-type="fig"} provides a visual comparison of NTCP versus mean thyroid dose for several thyroid volumes for the Boomsma et al[@bib18] model and the fitted model of the same form. In addition, 95% confidence bands are provided for the fitted model. These models were selected for comparison because the Boomsma et al model performed better on our internal data set and because they can be directly compared owing to being based on the same input parameters, whereas an EUD based model is not directly comparable to a model based on mean dose. The largest differences between the models are observed for the predictions for thyroid volumes of 25 mL.Figure 2Mean dose to the thyroid gland versus thyroid volume for patients with and without hypothyroidism (HT). A linear regression line and 95% confidence interval are displayed for each group.Figure 3Comparison of predicted NTCP values for different thyroid gland volumes. Comparison of predicted NTCP values for different thyroid gland volumes (colors) for the model previously published by Boomsma et al (dashed lines) and the model fit on our institution\'s data (solid lines). 95% confidence intervals (bands) are presented for the fitted model.

Discussion {#sec3}
==========

In a homogenous cohort of 396 OPC patients treated with IMRT, we examined the clinical and dosimetric correlates of RT-induced hypothyroidism and validated existing NTCP models for RT-induced hypothyroidism on a large sample cohort. Our data showed that patients with advanced tumor stage, positive nodal disease, bilateral neck irradiation, receipt induction chemotherapy, higher Dmean to TG, and smaller TG volume had significant risk of clinical HT in the univariate analysis. On multivariate analysis, Dmean and TG volume maintained a statistically significant association with clinical HT. Boomsma et al[@bib5] and Cella et al[@bib31] models for RT-induced hypothyroidism were tested on our institution's data in addition to models fit on the data set. Model performance was generally similar across all of the models with observed AUC values of approximately 0.7, with the exception of the model from Cella et al.[@bib31] Additionally, the corresponding EUD was significantly associated with HT on both univariate analysis and multivariable logistic regression. A linear relationship was observed between the TG volume and Dmean. Within the study cohort, patients with HT were predominately characterized by being female, with average aged, (median \[range\], 58\[36.5-82\] years old), diagnosed with BOT cancer, presented with advanced N stages, received induction chemotherapy concurrent chemoradition (IC ± CCRT), had HPV positive status, treated with split field IMRT, and underwent bilateral neck irradiation. Patients with HT had smaller TG volume compared with those without (11.8 compared with 12.8 mL, *P* \< .0001). Dmean was significantly higher in patients with clinical HT versus those without (50 vs 42 Gy, *P* \< .0001).

Differences in the performance between the model from Cella et al[@bib31] and the model from Boomsma et al[@bib18] and the fitted models could potentially be explained by differences in the patient populations on which the models were fitted, different study outcomes, and longer follow-up time. Cella et al[@bib31] developed their model on data from a cohort of patients treated for Hodgkin lymphoma with a median treatment dose of 32 Gy (range, 30-36).[@bib31], [@bib35] This is in contrast to our institution's cohort which received a median treatment dose of 69.96 Gy (range, 59.96-72.00). The median thyroid Dmean for the Cella et al[@bib31], [@bib35] study was reported for those patients with and without HT separately, with values of 31.5 Gy (range, 30.4-32.6) and 18.9 Gy (range, 15.8-29.8), respectively. However, for our cohort the median thyroid Dmean was 50.23 (range, 7.51-63.92; across all patients), which was greater than the maximum possible Dmean from their study. The Cella et al[@bib31] model was tested on a cohort of breast cancer patients reported by Johansen et al[@bib36] for which median thyroid Dmean was 31 Gy (range, 22-42) for patients with clinical HT (requiring treatment) and 31 Gy (range, 28-28) for those without HT. Cella et al[@bib31] reported AUC values for their model (Equation [3](#fd3){ref-type="disp-formula"}) of 0.874 for their internal data set and 0.914 for the Johansen et al[@bib36] data set. In contrast, the model from Boomsma et al[@bib18], [@bib36] (Equation [2](#fd2){ref-type="disp-formula"}) produced AUC values of 0.718 and 0.898,[@bib31] respectively, for the 2 data sets. The Boomsma et al[@bib18] model was fit for a cohort of head and neck cancer patients treated to dose in the range of 46 to 66 Gy; however, the median thyroid Dmean was not reported for this cohort. In this study we evaluated radiation-induced hypothyroidism as clinically evident hypothyroidism of CTCAE grade 2 or higher. This is in contrast to the previous studies which included both subclinical (laboratory determined) and clinical hypothyroidism. Such differences could further contribute to variations in model performance. Given the generally lower AUC values observed in our study (\~0.7) across both previously published models and fitted models compared with those AUC values observed in previous publications, it would seem that such models are less suited to predicting clinical hypothyroidism, though the Cella et al[@bib31] model did perform well for the Johansen et al[@bib36] cohort (clinical HT). The differences in thyroid Dmean for the various cohorts, lower values for Cella et al[@bib31] and Johansen et al[@bib36] and higher values for Boomsma et al[@bib18] and our cohort, would also contribute to differences in model performance. It is thus of great importance to continue to develop models based on different patient populations, such that a model whose input data most closely matches the intended application can be selected when evaluating RHT risk.

Our results indicated that NTCP models based on EUD with an *a* parameter greater than 1 (2, 3, 4, and 5 tested) performed the best, although the model performance was not significantly better than that of the Boomsma et al model. There may be some value in further investigation into the role of EUD in the NTCP for hypothyroidism; however, this is beyond the scope of this study.

Hypothyroidism is frequently observed after radiation[@bib1], [@bib2], [@bib3], [@bib4], [@bib5] and this phenomenon could be explained by RT-induced direct cell injury, microvascular insult[@bib1], [@bib37] and immune- mediated damage,[@bib38] which resulted in reduction of the TG volume.[@bib39] Such volumetric reduction was found to be correlated with the Dmean to the TG rather than the Dmax, which only affect a relative small volume of the TG.[@bib40] A thyroid volume effect in RHT development was found in our current research effort and others[@bib13], [@bib36], [@bib41]; there is a decrease in the risk of RHT with larger thyroid gland volumes and the volume of irradiated thyroid seems to be a risk factor for RHT.[@bib3]

Our study is the largest of its kind investigating the risk of RHT after IMRT for HNC patients with a comprehensive approach incorporating the clinical and dosimetric characteristics in the risk assessment. The study cohort is a homogenous sample of OPC patients treated with definitive intent and a median IMRT dose of 70 Gy. Our methodology accounts for the EUD in comparison to other approaches. However, our study has the caveats of retrospective design and utilization of single institution data set.

Multi-institutional collaboration and prospective data are incredibly needed to construct and validate the novel predictive models for treatment-induced toxicities. Although we excluded patients with unknown thyroid status at pre-RT time point, the retrospective nature of the study did not allow for accounting for the possibility of missing pre-RT subclinical hypothyroidism status. This caveat may introduce some bias. Prospective studies with frequent monitoring of the TSH level at multiple time points (baseline, during RT and shortly after RT (during the acute or subacute phase \[up to 6 months after RT\]) are needed to account for the fluctuation nature of the TSH results, false laboratory results and possibility of spontaneous recovery of pre-RT and acute or subacute subclinical hypothyroidism, which may affect the accuracy of the assessment of the thyroid status later and identify patients with late RT-induced hypothyroidism.

Our data confirms that thyroid volume and mean thyroid radiation therapy dose are important predictors of clinical radiation therapy-induced hypothyroidism. Accordingly, personalized plan optimization, based on individual thyroid volume, is recommended to reduce the risk of clinically relevant hypothyroidism after IMRT for OPC. In the era of the HPV-driven OPC, rapidly growing numbers of young survivors live longer with treatment morbidities, thus, maintaining the functional outcome is the metric of therapeutic success.

Supplementary data {#appsec1}
==================
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[^1]: *Abbreviations:* Dmean = mean dose; HPV = human papillomavirus; HT = hypothyroidism; IMRT = intensity-modulated radiation therapy; RT = radiation therapy; SD = standard deviation; TG = thyroid gland.

[^2]: Significant *P* value; *P* ≤ .0.

[^3]: *Abbreviations:* AUC = area under the curve; Dmean = mean dose; FDR = false discovary rate; LogWorth = --log10\[*P* value\] = such that *P* = .01 is equivalent to a LogWorth of 2.0, *P* = .001 is denoted by LogWorth of 3.0, etc; ROC = receiver operating characteristic; TG = thyroid gland.

[^4]: *Abbreviations*: AUC = area under the curve; CI = confidence interval; SD = standard deviation.

[^5]: AUC values from ROC curve analysis for each model are presented and AUC values for fitted models are compared with previously published models according to DeLong test for correlated ROC curves.
